Mohammad Gholami

Dr. Mohammad Gholami


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
MFMojdeh Amini Faskhoudi
Mojdeh Amini Faskhoudi
PMPejman Molaei
Pejman Molaei
MSMehrdokht Sadrkhanloo
Mehrdokht Sadrkhanloo
SOSima Orouei
Sima Orouei
MHMehrdad Hashemi
Mehrdad Hashemi
MGMohammad Gholami
Mohammad Gholami

26 January 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
EHEbrahim Hazrati
Ebrahim Hazrati
MGMohammad Gholami
Mohammad Gholami
RFRamin Hamidi Farahani
Ramin Hamidi Farahani
KGKhodayar Ghorban
Khodayar Ghorban
MGMorteza Ghayomzadeh
Morteza Ghayomzadeh
NRNegin Hosseini Rouzbahani
Negin Hosseini Rouzbahani

1 January 2019 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
MFMolood Farrokhi
Molood Farrokhi
MGMohammad Gholami
Mohammad Gholami
MMMinoo Mohraz
Minoo Mohraz
WMWilli McFarland
Willi McFarland
KBKazem Baesi
Kazem Baesi
LALadan Abbasian
Ladan Abbasian
Background: Antiretroviral (ARV) therapy extends life for persons living with HIV. Antiretroviral treatment (ART) has been rapidly expanding coverage around the world, including in Iran. However, ART drug resistance also rapidly develops with expanding use and limits effectiveness and treatment options. The aim of this study was to monitor the appearance of new mutations conferring HIV pretreatment drug resistance in the treatment of naïve patients with HIV in Iran. Materials and Methods: Blood samples were obtained from ARV treatment-naïve patients from 8 different provinces in Iran in 2016 for genotyping for drug resistance mutations. Results: Sequences were successfully obtained from 90 specimens. Of these, 2 (2%) mutations conferring resistance to protease inhibitors, 2 (3%) conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs), and 9 (13%) conferring resistance to non-NRTI (NNRTI) were detected. Any ARV-resistant drug mutation was found in 11 patients (12%). Conclusion: Nearly one in 8 ARV-naïve patients had mutations associated with NNRTI resistance in diverse areas of Iran in 2016. Iranian ARV therapy guideline for HIV could consider non-NNRTI-based first-line therapies and expand routine drug resistance testing before treatment initiation as according to HIV drug resistance recommendations of the World Health Organization.

15 December 2016 in Intervirology
Verified
Journal Article
Closed access
MFMolood Farrokhi
Molood Farrokhi
SMSamaneh Moallemi
Samaneh Moallemi
KBKazem Baesi
Kazem Baesi
SASara Ahsani-Nasab
Sara Ahsani-Nasab
MGMohammad Gholami
Mohammad Gholami
MMMinoo Mohraz
Minoo Mohraz
Background: Increasing the accessibility of antiretroviral therapy (ART) has caused the emergence of drug resistance in patients receiving ART and in naïve patients. The aim of this study was to evaluate HIV subtype and drug resistance between naïve patients and ART-experienced patients. Methods: Blood samples were collected from 78 antiretroviral and naïve HIV-1 patients; antiretroviral-resistant mutations and subtyping were then determined by sequencing pol regions. Results: Phylogenetic analysis revealed that 96.1% of sequences belong to the CRF35-AD subtype. Transmitted drug resistance was determined in 14% of drug-naïve patients and 40% of ART-experienced patients. Conclusion: The findings of this study illustrated the importance of resistance testing before and during ART treatment. This study can be used to set up a best medicine strategy in Iranian guidelines.

1 January 2018 in Intervirology
Verified
Journal Article
Closed access
PDF file
MMMinoo Mohraz
Minoo Mohraz
KTKatayoun Tayeri
Katayoun Tayeri
HTHengameh Namdari Tabar
Hengameh Namdari Tabar
ZJZahra Bayat Jozani
Zahra Bayat Jozani
LSLeila Sadeghi
Leila Sadeghi
SBSaeed Bayanolhagh
Saeed Bayanolhagh
Aims: The aim of this study was to evaluate drug resistance patterns among Iranian people living with HIV who have taken antiretroviral therapy for 9–15 months. Methods: A cross-sectional study was conducted between December 2015 and May 2016. Two hundred fifty-two blood samples were collected from all eligible HIV-infected patients at fourteen healthcare settings, located in major provinces in Iran. The samples were examined for presence of drug resistance strains and viral load level. Moreover, a phylogenetic tree, using neighbor joining, was constructed and HIV subtypes were determined. Results: The most common subtypes were CRF35-AD (47.6%) and A1 (42.8%), followed by 45_CPX (4.8%) and C (4.8%). The resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors was reported as 19.2, 19.2, and 10.3%, respectively. M184I/V mutation was the most frequent (31.6%) mutation among NRTI-based regimens. Moreover, K103E/N was the most frequent (34.2%) NNRTI mutation. Conclusions: This is the first study to illuminate the emergence of the CPX genotype among Iranian patients. The drug resistance rate of NNRTIs was similar to that of NRTIs. By assessing drug resistance, it is possible to evaluate the efficacy of treatment and patient adherence to treatment.

1 September 2020 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MGMohammad Gholami
Mohammad Gholami
NRNeginHosseini Rouzbahani
NeginHosseini Rouzbahani
SSSiamakMirab Samiee
SiamakMirab Samiee
KTKatayoun Tayeri
Katayoun Tayeri
KGKhodayar Ghorban
Khodayar Ghorban
MMMinoo Mohraz
Minoo Mohraz